Hong Kong Clears Europharm Products Of Fungus, Plant Still Shut
This article was originally published in PharmAsia News
Hong Kong health authorities have now cleared all 359 of Europharm's drug products of containing a fungal growth found in gout products. Although the Hong Kong Department of Health said it plans to continue testing, it said examinations of 39 raw material samples from the drug maker uncovered none of the Rhizopus microsporus fungus implicated in at least six Hong Kong fatalities. But the department also said Europharm could not resume manufacturing operations until it has improved its production lines to the satisfaction of authorities. (Click here for more
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.